KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Basic) (2019 - 2025)

Aurinia Pharmaceuticals' EPS (Basic) history spans 7 years, with the latest figure at $1.6 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 15900.0% year-over-year to $1.6; the TTM value through Dec 2025 reached $2.17, up 4240.0%, while the annual FY2025 figure was $2.14, 5250.0% up from the prior year.
  • EPS (Basic) reached $1.6 in Q4 2025 per AUPH's latest filing, up from $0.24 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.6 in Q4 2025 to a low of -$0.4 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.02, with a median of -$0.08 recorded in 2023.
  • Peak YoY movement for EPS (Basic): tumbled 73.91% in 2021, then soared 15900.0% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.25 in 2021, then rose by 28.0% to -$0.18 in 2022, then fell by 5.56% to -$0.19 in 2023, then soared by 105.26% to $0.01 in 2024, then skyrocketed by 15900.0% to $1.6 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EPS (Basic) are $1.6 (Q4 2025), $0.24 (Q3 2025), and $0.16 (Q2 2025).